ea0092ps3-24-04 | Thyroid Eye Disease | ETA2023
Manousou Sofia
, Holmberg Mats
, Ekdahl Elin
, Malmgren Helge
, Skodell Lena
, Filipsson Nystrom Helena
Background: Graves orbitopathy (GO) is the most frequent and feared complication of GravesÂ’ disease. In moderate-severe cases, intravenous (iv) glucocorticoids (GC) is the first-line treatment while Rituximab (RTX) is recommended as second-line treatment in patients non-responsive to GC. But data is scarce and contradictory.Objective: To investigate if patients with GO and poor response to iv GC benefit from a switch to RTX early in the treatment co...